258 related articles for article (PubMed ID: 17897752)
1. Modulation of host metabolism as a target of new antivirals.
Ikeda M; Kato N
Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
[TBL] [Abstract][Full Text] [Related]
2. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
3. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
4. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle.
Park SB; Boyer A; Hu Z; Le D; Liang TJ
Antivir Ther; 2019; 24(5):371-381. PubMed ID: 30880685
[TBL] [Abstract][Full Text] [Related]
7. [Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents].
Watashi K; Shimotohno K
Uirusu; 2005 Jun; 55(1):105-10. PubMed ID: 16308536
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
9. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
[TBL] [Abstract][Full Text] [Related]
10. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon.
Ikeda M; Kato N
J Pharmacol Sci; 2007 Oct; 105(2):145-50. PubMed ID: 17928739
[TBL] [Abstract][Full Text] [Related]
11. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
[TBL] [Abstract][Full Text] [Related]
13. HCV research and anti-HCV drug discovery: toward the next generation.
Wakita T
Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents.
Shahidi M; Tay ESE; Read SA; Ramezani-Moghadam M; Chayama K; George J; Douglas MW
J Gen Virol; 2014 Nov; 95(Pt 11):2468-2479. PubMed ID: 25053565
[TBL] [Abstract][Full Text] [Related]
15. Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
Escuret V; Martin A; Durantel D; Parent R; Hantz O; Trépo C; Menguy T; Bottius E; Dardy J; Maral J; Escary JL; Zoulim F
Antimicrob Agents Chemother; 2006 Dec; 50(12):3984-91. PubMed ID: 17030563
[TBL] [Abstract][Full Text] [Related]
16. New therapies on the horizon for hepatitis C: are we close?
De Francesco R; Rice CM
Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468
[TBL] [Abstract][Full Text] [Related]
17. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
Pugnale P; Herrmann E; Neumann AU; Pawlotsky JM; Schalm SW; Ferrari C; Homburger Y; Zeuzem S; Negro F;
J Hepatol; 2008 Jun; 48(6):932-8. PubMed ID: 18433918
[TBL] [Abstract][Full Text] [Related]
19. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
Watashi K; Shimotohno K
Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C: therapeutic perspectives.
Cornberg M; Wedemeyer H; Manns MP
Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
